Goldiam's Lab-Grown Leap: Shareholder Win?

Goldiam International has made a bold shift to lab-grown diamonds (LGD), with these products now forming 90.5% of its Q3 FY26 export sales, up from 80% last year. This pivot drove revenue up 18% to ₹3,397 million and profit after tax by 37.4% to ₹684 million. EBITDA margins expanded to 26.7%, boosted by LGD's higher profitability over natural diamonds. Financial Boost for Shareholders For nine months of FY26, revenue grew 29.8% to ₹7,773 million, PAT rose 42% to ₹1,334 million, and cash reserves hit ₹5,041 million. The company stays debt-free with strong liquidity, supporting dividends or buybacks at 50% of PAT. This creates real value, with EPS up 31.8% to ₹6.14 in Q3. Strategic Edge in LGD Market Unlike Tanishq or Kalyan, Goldiam focuses on exports, especially to the US, using a US-origin casting model to dodge tariffs. Its ORIGEM brand expands retail, targeting 20-25 stores by March 2026, tapping sustainable demand. Vertical integration—from growing LGD to jewelry—ensures cost control and quality. Benefits Outweigh Risks This strategy benefits shareholders through superior margins, rapid growth, and market leadership in ethical diamonds. Risks like LGD price drops exist, but strong orders (₹2,000 million) and new clients in Europe/Middle East mitigate them. Overall, it's a game-changer, enhancing returns and positioning Goldiam for sustained gains.